[{"orgOrder":0,"company":"GC Cell","sponsor":"Rivaara Labs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Autologous T-cell Immunotherapy","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"GC Cell \/ GC Cell","highestDevelopmentStatusID":"12","companyTruncated":"GC Cell \/ GC Cell"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"MG1111","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Marzeptacog Alfa","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"EuBiologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Euvichol","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GC Biopharma \/ Eubiologics","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Eubiologics"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"GC1126A","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Immetas Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"mRNA Therapeutic","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"GC Biopharma \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"GC1109","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"4","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human-stwk","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"5","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Soleo Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"KabaFusion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Biopharma \/ KabaFusion","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ KabaFusion"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"alpha-galactosidase A","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Biopharma \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"GC Cell","sponsor":"PT Bifarma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"CIK-based Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Cell \/ PT Bifarma","highestDevelopmentStatusID":"12","companyTruncated":"GC Cell \/ PT Bifarma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novelty Nobility","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Novelty Nobility"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Biopharma \/ GC Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GC Biopharma \/ Novel Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by GC Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : GC1130A' is a first-in-class treatment high-quality recombinant protein that is administered via ICV injection to bypass the BBB for the treatment of MPS IIIA.

Brand Name : GC1130A

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 25, 2024

Lead Product(s) : Recombinant Human Heparan N-sulfatase

Therapeutic Area : Genetic Disease

Highest Development Status : Phase I

Sponsor : Novel Pharma

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.

Brand Name : Undisclosed

Molecule Type : Large molecule

Upfront Cash : Undisclosed

October 28, 2024

Lead Product(s) : ADC-based Therapy

Therapeutic Area : Ophthalmology

Highest Development Status : Undisclosed

Sponsor : Novelty Nobility

Deal Size : Undisclosed

Deal Type : Agreement

blank

03

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.

Brand Name : Undisclosed

Molecule Type : Large molecule

Upfront Cash : Undisclosed

October 28, 2024

Lead Product(s) : Antibody-based Therapy

Therapeutic Area : Ophthalmology

Highest Development Status : Discovery

Recipient : Novelty Nobility

Deal Size : Undisclosed

Deal Type : Agreement

blank

04

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Bifarma will be granted the exclusive rights to develop, manufacture, and commercialize Immuncell-LC, an anti-cancer immune cell therapy, for 15 years.

Brand Name : Immuncell-LC

Molecule Type : Cell and Gene therapy

Upfront Cash : Undisclosed

September 10, 2024

Lead Product(s) : CIK-based Cell Therapy

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : PT Bifarma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

05

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : ALYGLO (immune globulin intravenous, human-stwk) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults.

Brand Name : Alyglo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 09, 2024

Lead Product(s) : Immune Globulin Intravenous, Human

Therapeutic Area : Immunology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : GC1134A/HM15421 is a long-acting alpha-galactosidase that can be administered subcutaneously once a month in patients with fabry disease, also to improve patient's convenience.

Brand Name : GC1134A

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 03, 2024

Lead Product(s) : alpha-galactosidase A

Therapeutic Area : Genetic Disease

Highest Development Status : IND Enabling

Sponsor : Hanmi Pharmaceutical

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : GC Biopharma partners with KabaFusion for the distribution to provide Alyglo (Immune Globulin Intravenous, Human) for treating primary humoral immunodeficiency for Adults, 17 years and older.

Brand Name : Alyglo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

July 30, 2024

Lead Product(s) : Immune Globulin Intravenous, Human

Therapeutic Area : Immunology

Highest Development Status : Approved

Sponsor : KabaFusion

Deal Size : Undisclosed

Deal Type : Partnership

blank

08

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Soleo partnership with GC Biopharma to dispense Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for treating Adults with Primary Humoral Immunodeficiency.

Brand Name : Alyglo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

July 16, 2024

Lead Product(s) : Immune Globulin Intravenous, Human

Therapeutic Area : Immunology

Highest Development Status : Approved

Recipient : Soleo Health

Deal Size : Undisclosed

Deal Type : Partnership

blank

09

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : GC1130A (recombinant human heparan N-sulfatase) is an intracerebroventricular enzyme replacement therapy candidate. It is being evaluated for the treatment of sanfilippo syndrome type A.

Brand Name : GC1130A

Molecule Type : Large molecule

Upfront Cash : Not Applicable

June 10, 2024

Lead Product(s) : Recombinant Human Heparan N-sulfatase

Therapeutic Area : Genetic Disease

Highest Development Status : IND Enabling

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : GC1130A (recombinant human heparan N-sulfatase), is an intracerebroventricular (ICV) enzyme replacement therapy candidate under investigation for the treatment of sanfilippo syndrome.

Brand Name : GC1130A

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 20, 2024

Lead Product(s) : Recombinant Human Heparan N-sulfatase

Therapeutic Area : Genetic Disease

Highest Development Status : Preclinical

Sponsor : Novel Pharma

Deal Size : Not Applicable

Deal Type : Not Applicable

blank